Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Gene therapy
- Key elements in gene transfer
- Viral infection - cell entry
- Viral infection - viral replication
- Creating a viral vector
- Therapeutic activity
- Therapeutic activity after cell division
- Clinical gene therapy: ex vivo milestones
- Clinical gene therapy: in vivo milestones
- Advancing gene therapy: the challenges
- Limitations of expression cassette
- Properties & limitations of transfer vector (1)
- Properties & limitations of transfer vector (2)
Topics Covered
- Gene therapy
- Key elements in gene transfer
- Viral infection
- Cell entry
- Viral replication
- Creating a viral vector
- Therapeutic activity
- Therapeutic activity after cell division
- Clinical gene therapy: ex vivo and in vivo milestones
- Advancing gene therapy: the challenges
- Limitations of expression cassette
- Properties & limitations of transfer vector
Talk Citation
Naldini, L. (2014, August 5). Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/EMQR8196.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Luigi Naldini has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome 1
Published on August 5, 2014
47 min
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
So hello, everybody.
This so the first recording in
this series of gene therapy.
I am in the Luigi Naldini.
I am the director of the
San Raffaele-Telethon
Institute for Gene
Therapy in Milan, Italy.
And I will be discussing,
in this first lecture,
general features of gene
therapy and vectors.
0:22
In the first slide, we are
mentioning the key strategies
in gene transfer and gene therapy.
Gene addition, which
is the insertion
of new genetic information in a cell
to replace a malfunctioning gene
and replacing its function, or
to instruct a novel function
to that cell-- for
instance, to make that cell
resistant to an infectious
agent or to help
that cell better fight the cancer.
These are the most common strategies
in gene transfer and therapy today.
There are, however,
additional strategies, which
are gene subtraction--
in which case,
we aim to disrupt or inhibit an
endogenous gene to essentially
prevent its expression, again, to
enable maybe resistance to a virus
or to fight a dominant
oncogenic mutation.
And gene editing, which
is a more advanced
of gene therapy in which, rather
than adding or subtracting genes,
we are actually rewriting the
genetic sequencing in the cell,
most often to correct directly in situ, a genetic inherited
mutation, or to insert novel
sequence at this specific site.
And gene editing can be performed
at the RNA level, in which case
we would modify RNA transcript,
either by, for instance,
forcing axon skipping
or trans-splicing.
Or in a more stable at the DNA
level by either disrupting genes
or forcing homologous
recombination through the use
of artificial nucleuses.
And all of these strategies
will be, of course,
discussed in detail
in selected talks.
Hide